GB946576A - Improvements in or relating to steroids - Google Patents

Improvements in or relating to steroids

Info

Publication number
GB946576A
GB946576A GB43596/60A GB4359660A GB946576A GB 946576 A GB946576 A GB 946576A GB 43596/60 A GB43596/60 A GB 43596/60A GB 4359660 A GB4359660 A GB 4359660A GB 946576 A GB946576 A GB 946576A
Authority
GB
United Kingdom
Prior art keywords
compound
oso2r11
opo3h2
fluorine
representing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB43596/60A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US51298A external-priority patent/US3239544A/en
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB946576A publication Critical patent/GB946576A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Abstract

The invention comprises a compound having the formula: <FORM:0946576/C2/1> wherein A represents hydroxyl, -OPO3H2, -OSO2R11 wherein R11 is an alkyl or aryl radical, or O Acyl the term acyl representing the acyl radical of an organic carboxylic acid. R1 represents a b -hydroxy or keto group, X represents <FORM:0946576/C2/2> or <FORM:0946576/C2/3> , R being attached at the 2-position and representing hydrogen or methyl, Z represents hydrogen methyl or fluorine and Hal represents chlorine, fluorine, bromine or iodine provided that 1/. when A represents OPO3H2 or OSO2R11 Hal represents fluorine and 2/. when X represents -CH=CH-, Z represents methyl or fluorine and processes for the preparation thereof by dehydrating a compound having the formula: <FORM:0946576/C2/4> wherein Ac, X, and Z are as above defined, hypohalogenating to form the corresponding 9a -chloro,bromo or iodo derivative and then if desired epoxidising to produce a compound having the general formula: <FORM:0946576/C2/5> wherein Ac, X and Z are as above defined, and then reacting this latter compound with aqueous hydrogen fluoride or aqueous hydrogen chloride to form the corresponding 9a -fluoro- or 9a -chloro derivative and then if desired oxidising or hydrolysing to produce the corresponding 11-keto 21-ester or free 21-hydroxy compound; subsequently the 21-hydroxy compound may be treated with an alkyl or aryl sulphonyl halide to obtain a 21-OSO2R11 compound which may be treated with an alkali metal iodide to obtain a 21-iodo compound or silver dihydrogen phosphate to obtain a 21-OPO3H2 compound; treating the 21-OSO2 R11 or the 21-iodo compound with a metal fluoride produces the 21-fluoro compounds. In the process above the dehydration step may be effected with N-bromacetamide and anhydrous sulphur dioxide, the hypohalogenation step with perchloric acid and N-bromoacetamide or N-iodo-succinimide, the epoxidation step with anhydrous potassium acetate and the oxidation step with chromic acid. In an alternative process the 21-phosphate is obtained by treating the 21-sulphonate with phosphoric acid in the presence of a tertiary amine and then acidifying the 21-hydrogen phosphate so produced to obtain the free 21-phosphate compound. Specifications 850,833, 872,112, 873,219, 946,578 and 946,579 are referred to.ALSO:Pharmaceutic compositions having anti-inflammatory activity and containing a compound of the formula: <FORM:0946576/A5-A6/1> wherein A represents -OH, -OPO3H2, -OSO2R11 wherein R11 is an alkyl or aryl radical (1-10 carbon atoms) or -OAc, the term Ac representing the acyl radical of an organic carboxylic acid particularly a hydrocarbon carboxylic acid having 1-12 carbon atoms, R1 represents b -OH or Keto, X represents <FORM:0946576/A5-A6/2> or <FORM:0946576/A5-A6/3> , R being attached at the 2-position and representing H or CH3, 2 represents H, CH3, or F and Hal represents halogen provided that: (1) when A represents -OPO3H2 or -OSO2R11 Hal represents fluorine; and (2) when X represents -CH = CH-, Z represents CH3 or F, and a coacting antibiotic, are administered orally as pills, tablets, capsules, syrups or elixirs, in liquid forms for injectable products, or topically as ointments, creams or lotions. Specifications 850,833, 872,112, 873,219, 946,578 and 946,579 are referred to.
GB43596/60A 1960-01-11 1960-12-19 Improvements in or relating to steroids Expired GB946576A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US144960A 1960-01-11 1960-01-11
US3676060A 1960-06-17 1960-06-17
US51298A US3239544A (en) 1960-08-23 1960-08-23 16-fluoro-11-hydroxy steroids of the pregnane series

Publications (1)

Publication Number Publication Date
GB946576A true GB946576A (en) 1964-01-15

Family

ID=27356927

Family Applications (2)

Application Number Title Priority Date Filing Date
GB43596/60A Expired GB946576A (en) 1960-01-11 1960-12-19 Improvements in or relating to steroids
GB38029/62A Expired GB946579A (en) 1960-01-11 1960-12-19 Improvements in or relating to steroids and the manufacture thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB38029/62A Expired GB946579A (en) 1960-01-11 1960-12-19 Improvements in or relating to steroids and the manufacture thereof

Country Status (4)

Country Link
BE (1) BE598999A (en)
CH (2) CH407113A (en)
FR (1) FR1088M (en)
GB (2) GB946576A (en)

Also Published As

Publication number Publication date
GB946579A (en) 1964-01-15
FR1088M (en) 1962-01-29
CH422774A (en) 1966-10-31
CH407113A (en) 1966-02-15
BE598999A (en) 1961-07-11

Similar Documents

Publication Publication Date Title
GB902292A (en) Improvements in or relating to steroids and the manufacture thereof
GB946576A (en) Improvements in or relating to steroids
GB1060793A (en) Improvements in or relating to steroids and the manufacture thereof
GB946577A (en) Improvements in or relating to steroids and the manufacture thereof
GB959792A (en) Improvements in or relating to steroids
GB935116A (en) New cyclopentanophenanthrene derivatives and processes for the production thereof
GB1043995A (en) Improvements in or relating to 5,10-methylene-19-nor-steroids and 5,10-seco-5,19-cyclo-10-fluoro-steroids
GB865673A (en) Improvements in or relating to steroids and the manufacture thereof
GB894604A (en) Improvements in or relating to steroids and the manufacture thereof
GB881901A (en) Improvements in or relating to steroids and the manufacture thereof
GB889779A (en) Improvements in or relating to steroids and the manufacture thereof
GB894642A (en) Improvements in or relating to steroids and the manufacture thereof
GB839698A (en) Steroids and the synthesis thereof
GB872112A (en) Improvements in or relating to steroids and the manufacture thereof
GB907812A (en) Improvements in or relating to steroids and the manufacture thereof
GB873219A (en) Improvements in or relating to steroids and the manufacture thereof
GB878622A (en) Improvements in or relating to steroids and the manufacture thereof
GB873608A (en) Improvements in or relating to steroids and the manufacture thereof
GB886861A (en) Steroid compounds
GB1022042A (en) Improvements in or relating to steroids and the manufacture thereof
GB852680A (en) 2-alpha-methyl-4-pregnenes and method of preparing the same
GB872108A (en) Improvements in or relating to steroids and the manufacture thereof
GB861471A (en) Improvements in or relating to steroids and the manufacture thereof
GB741013A (en) Steroid compounds
GB893146A (en) Improvements in or relating to steroids and the manufacture thereof